Clinical case of effective treatment of invasive mycosis caused by polyresistant strain of Candida auris

The objective was to demonstrate a clinical case of effective treatment of a patient with invasive mycosis caused by Candida auris with drug resistance to antifungal drugs by a combination of micafungin and amphotericin B lipid complex.

Materials and methods. International databases such as MEDLINE, EMBASE, Web of Science and Scopus until 2023 were used for the analysis.

Results. We have demonstrated the effective case of treatment of invasive candidiasis caused by the polyresistent pathogen Candida auris with the combination of micafungin and amphotericin B in the patient who underwent mitral valve replacement, which was complicated by acute aortic dissection, acute thrombosis of the superior mesenteric artery, septic shock and a number of other nosocomial infections.

Conclusion. Due to the high resistance of Candida auris to all antifungal drugs currently existing in the world, the combination of several antifungal drugs is an advantage over monotherapy. However, given the lack of approved standards and guidelines for the treatment of patients with this infection, and insufficient clinical experience in the management of such patients, further search for effective treatment regimens for infections caused by Candida auris and the development of new antifungal agents that can overcome the resistance of this pathogen are necessary.

1. Ivanov A.A., Kulichenko T.V. Candida Auris: problems in diagnostics and management. Current Pediatrics, 2020, vol. 19, no. 1, pp. 20–25. (In Russ.) DOI: 10.15690/vsp.v19i1.2081.

2. Koltsov I.P., Strelnikova N.V., Vitko E.V. et al. Microbiological properties of opportunistic saccharomycetes of the genus Candida in chronic, recurrent infectious inflammatory processes (literature review). Pacific Medical Journal, 2023, no. 1, pp. 19–26. (In Russ.) DOI: 10.34215/1609-1175-2023-1-19-26.

3. SATC Program (Strategy for Anrimicrobial Therapy Control) for in-patient care medical care: Russian clinical guidelines. S.V. Yakovlev, N.I. Briko, S.V. Sidorenko, D.N. Protsenko, eds., Moscow, Izd-vo Pero Publ., 2018, 156 p.4. Chen J., Tian S., Han X. et al. Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris // BMC Infect Dis. – 2020. – Vol. 20, № 1. – P. 827. DOI: 10.1186/s12879-020-05543-0.

4. Cleveland A.A., Farley M.M., Harrison L.H. et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011 // Clin Infect Dis. – 2012. – Vol. 55, № 10. – P. 1352. DOI: 10.1093/cid/cis697.

5. Cleveland A.A., Harrison L.H., Farley M.M. et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008–2013: results from population-based surveillance // PLoS One. – 2015. – Vol. 10, № 3. – P. e0120452. DOI: 10.1371/journal.pone.0120452.

6. Dadar M., Tiwari R., Karthik K. et al. Candida albicans - Biology, molecular characterization, pathogenicity, and advances in diagnosis and control – An update // Microb Pathog. – 2018. – Vol. 117. – P. 128. DOI: 10.1016/j.micpath.2018.02.028.

7. Fakhim H., Chowdhary A., Prakash A. et al. In Vitro Interactions of Echinocandins with Triazoles against Multidrug-Resistant Candida auris // Antimicrob Agents Chemother. – 2017. – Vol. 61, № 11. – P.e01056–17. DOI: 10.1128/AAC.01056-17.

8. Fortún J., Meije Y., Buitrago M. J. et al. Clinical validation of a multiplex real-time PCR assay for detection of invasive candidiasis in intensive care unit patients // J AntimicrobChemother. – 2014. – Vol. 69, № 11. – P. 3134. DOI: 10.1093/jac/dku225.

9. Hachem R., Hanna H., Kontoyiannis D. et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy // Cancer. – 2008. – Vol. 112, № 11. – P. 2493. DOI: 10.1002/cncr.23466.

10. Hesstvedt L., Gaustad P., Andersen C. T. et al. Twenty-two years of candidaemia surveillance: results from a Norwegian national study // Clin Microbiol Infect. – 2015. – Vol. 21, № 10. – P. 938. DOI: 10.1016/j.cmi.2015.06.008

11. Lamoth F., Lockhart S. R., Berkow E. L. et al. Changes in the epidemiological landscape of invasive candidiasis // J Antimicrob Chemother. – 2018. – Vol. 73, № 1. – P. i4. DOI: 10.1093/jac/dkx444.

12. Larkin E., Hager C., Chandra J. et al. The emerging pathogen candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation // Antimicrob Agents Chemother. – 2017. – Vol. 61, № 5. – P. e02396. DOI: 10.1128/AAC.02396-16.

13. Lockhart S. R., Etienne K. A., Vallabhaneni S. et al. simultaneous emergence of multidrug-resistant candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses // Clin Infect Dis. – 2017. – Vol. 64, № 2. – P. 134. DOI: 10.1093/cid/ciw691.

14. Lockhart S. R., Messer S. A., Gherna M. et al. Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature // J Clin Microbiol. – 2009. – Vol. 47, № 4. – P. 1216. DOI: 10.1128/JCM.02315-08.

15. Quindós G. Epidemiology of candidaemia and invasive candidiasis. A changing face // Rev Iberoam Micol. – 2014. – Vol. 31, № 1. – P. 42. DOI: 10.1016/j. riam.2013.10.001.

16. Quindós G. Marcos-Arias C., San-Millán R. et al. The continuous changes in the aetiology and epidemiology of invasive candidiasis: from familiar Candida albicans to multiresistant Candida auris // IntMicrobiol. – 2018. – Vol. 21, № 3. – P. 107. DOI: 10.1007/s10123-018-0014-1.

17. Ruiz-Gaitán A., Moret A. M., Tasias-Pitarch M. et al. An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospital // Mycoses. – 2018. – Vol. 61, № 7. – P. 498. DOI: 10.1111/myc.12781.

18. Satoh K., Makimura K., Hasumi Y. et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital // Microbiol Immunol. – 2009. – Vol. 53, № 1. – P. 41. DOI: 10.1111/j.1348-0421.2008.00083.x.

19. Treviño-Rangel R. J., González G. M., Montoya A. M. et al. Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review // J Fungi (Basel). – 2022. – Vol. 8, № 11. – P. 1144. DOI: 10.3390/jof8111144.

20. Vinayagamoorthy K., Pentapati K. C., Prakash H. Prevalence, risk factors, treatment and outcome of multidrug resistance Candida auris infections in Coronavirus disease (COVID-19) patients: A systematic review // Mycoses. – 2022. – Vol. 65, № 6. – P. 613. DOI: 10.1111/myc.13447.

21. https://www.cdc.gov/fungal/candida-auris/index.html